Healthcare -
Biotechnology - NASDAQ - DE
$ 3.1
1.31 %
$ 695 M
Market Cap
6.33
P/E
1. INTRINSIC VALUE
Balance Sheet
CureVac N.V.
| Current Assets | 478 M |
| Cash & Short-Term Investments | 405 M |
| Receivables | 39.5 M |
| Other Current Assets | 33.8 M |
| Non-Current Assets | 310 M |
| Long-Term Investments | -4 K |
| PP&E | 279 M |
| Other Non-Current Assets | 31.2 M |
| Current Liabilities | 186 M |
| Accounts Payable | 46.4 M |
| Short-Term Debt | 5 M |
| Other Current Liabilities | 135 M |
| Non-Current Liabilities | 84.9 M |
| Long-Term Debt | 36.8 M |
| Other Non-Current Liabilities | 48.1 M |
EFFICIENCY
Earnings Waterfall
CureVac N.V.
| Revenue | 53.8 M |
| Cost Of Revenue | 124 M |
| Gross Profit | -70.6 M |
| Operating Expenses | 204 M |
| Operating Income | -274 M |
| Other Expenses | -14 M |
| Net Income | -260 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CureVac N.V.
| Net Income | -260 M |
| Depreciation & Amortization | 23.4 M |
| Capital Expenditures | -55.2 M |
| Stock-Based Compensation | 7.7 M |
| Change in Working Capital | -68.3 M |
| Others | 45.4 M |
| Free Cash Flow | -323 M |
Wall Street Analysts Price Targets
CureVac N.V.
CVAC has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CVAC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CureVac N.V.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®.
accessnewswire.com
- 1 week ago
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025.
seekingalpha.com
- 1 month ago
2 Small-Cap Stocks Set to Shine in a Bull Market
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
marketbeat.com
- 2 months ago
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
zacks.com
- 3 months ago
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants Charlie Yang - Bank of America Merrill Lynch CJ Yeh - Leerink Partners Roy Buchanan - Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call.
seekingalpha.com
- 3 months ago
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.
accesswire.com
- 3 months ago
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024.
accesswire.com
- 3 months ago
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.
accesswire.com
- 3 months ago
CureVac to Present at the 12th International mRNA Health Conference
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024.
accesswire.com
- 3 months ago
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.
accesswire.com
- 4 months ago
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
reuters.com
- 4 months ago
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in patients without pre-existing T-cell activity against encoded cancer antigens CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection 100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 13, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today presented compelling data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress.
accesswire.com
- 5 months ago
8. Profile
Summary
CureVac N.V. CVAC
COUNTRY
DE
INDUSTRY
Biotechnology
MARKET CAP
$ 695 M
Dividend Yield
0.00%
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Contact
Friedrich-Miescher-Strasse 15, Tübingen, 72076
https://www.curevac.com
IPO
Date
Aug. 14, 2020
Employees
999
Officers
Dr. Myriam Mendila M.D.
Chief Scientific Officer, Head of R&D, MD & Member of the Management Board
Mr. Thaminda Ramanayake
Chief Business Officer & Member of Executive Board
Mr. Thorsten Schuller
Head of Corporate Communications
Slavica Stevanovic-Heck
Head of Human Resources
Mr. Axel-Sven Malkomes
Chief Financial Officer & Member of Executive Board
Mr. Marco Rau L.L.M., Ph.D.
General Counsel
Dr. Alexander Zehnder M.B.A., M.D.
Chief Executive Officer, MD & Member of Management Board
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
Senior Vice President & Area Head of Oncology
Dr. Malte Greune Ph.D.
Chief Operating Officer, Member of Management Board & MD
Dr. Sarah Fakih
Vice President Corporate Communications & Investor Relations